DrugPatentWatch Database Preview

Drugs in Development Information for MN-166

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug MN-166?

MN-166 is an investigational drug.

There have been 11 clinical trials for MN-166. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1^st 2019.

The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).

There are eight hundred and four US patents protecting this investigational drug and seven international patents.

Summary for MN-166

US Patents	804
International Patents	7,602
US Patent Applications	3,377
WIPO Patent Applications	1,287
Japanese Patent Applications	1,183
Clinical Trial Progress	Phase 1 (2019-10-01)
Vendors	90

Recent Clinical Trials for MN-166

Title	Sponsor	Phase
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS	MediciNova	Phase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS	MediciNova	Phase 2/Phase 3
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers	MediciNova	Phase 1

See all MN-166 clinical trials

Clinical Trial Summary for MN-166

Top disease conditions for MN-166

Top clinical trial sponsors for MN-166

See all MN-166 clinical trials

US Patents for MN-166

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
MN-166		Heterocyclic compound	Takeda Pharmaceutical Company Limited (Osaka, JP)
MN-166		Therapeutic approaches for treating Parkinson's disease	Pharnext (Issy les Moulineaux, FR)
MN-166		Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells	Selecta Biosciences, Inc. (Watertown, MA)
MN-166		Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag	The Catholic University of America (Washington, DC)
MN-166		Ultra-pure agonists of guanylate cyclase C, method of making and using same	SYNERGY PHARMACEUTICALS, INC. (New York, NY)

International Patents for MN-166

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
MN-166	Canada	CA2961033	2034-09-11
MN-166	European Patent Office	EP3192791	2034-09-11
MN-166	Japan	JPWO2016039408	2034-09-11
MN-166	World Intellectual Property Organization (WIPO)	WO2016039408	2034-09-11
MN-166	Australia	AU2012222348	2031-03-01